2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of …
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and can complicate the majority of cardiovascular and respiratory …
clinical conditions and can complicate the majority of cardiovascular and respiratory …
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary …
M Humbert, G Kovacs, MM Hoeper… - European heart …, 2022 - academic.oup.com
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …
clinical conditions and may be associated with a variety of cardiovascular and respiratory …
[PDF][PDF] 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …
Epidemiology and treatment of pulmonary arterial hypertension
EMT Lau, E Giannoulatou, DS Celermajer… - Nature Reviews …, 2017 - nature.com
In the past 2 decades, major changes have occurred in the epidemiological and treatment
landscape of pulmonary arterial hypertension (PAH). Previously regarded as a disease of …
landscape of pulmonary arterial hypertension (PAH). Previously regarded as a disease of …
Pulmonary arterial hypertension: epidemiology and registries
MD McGoon, RL Benza, P Escribano-Subias… - Journal of the American …, 2013 - jacc.org
Registries of patients with pulmonary arterial hypertension (PAH) have been instrumental in
characterizing the presentation and natural history of the disease and provide a basis for …
characterizing the presentation and natural history of the disease and provide a basis for …
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European …
Thus, the task of writing Guidelines or Expert Consensus documents covers not only the
integration of the most recent research, but also the creation of educational tools and …
integration of the most recent research, but also the creation of educational tools and …
Advances in therapeutic interventions for patients with pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a disease characterized by progressive
remodeling of the distal pulmonary arteries, resulting in the loss of vascular cross-sectional …
remodeling of the distal pulmonary arteries, resulting in the loss of vascular cross-sectional …
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
Background Treatments for pulmonary arterial hypertension have been mainly studied in
patients with advanced disease (WHO functional class [FC] III and IV). This study was …
patients with advanced disease (WHO functional class [FC] III and IV). This study was …
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis
TE King Jr, KK Brown, G Raghu… - American journal of …, 2011 - atsjournals.org
Rationale: A previous trial of bosentan in idiopathic pulmonary fibrosis (IPF) showed a trend
to delayed IPF worsening or death. Also, improvements in some measures of dyspnea and …
to delayed IPF worsening or death. Also, improvements in some measures of dyspnea and …
Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions
SU Vorrink, Y Zhou, M Ingelman-Sundberg… - Toxicological …, 2018 - academic.oup.com
High failure rates of drug candidates in the clinics, restricted-use warnings as well as
withdrawals of drugs in postmarketing stages are of substantial concern for the …
withdrawals of drugs in postmarketing stages are of substantial concern for the …